Chemotherapeutic Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Fertility and Anticancer Activity.
Here, we demonstrate a 2-fold increase in nanoparticle accumulation in the ovaries during female mouse ovulation compared to the non-ovulatory stage following intravenous administration. Accumulation in the reproductive system is favored by nanoparticles smaller than 100 nm.
“Throughout the female menstrual cycle, physiological changes occur that affect the biodistribution of nanoparticles within the reproductive system.”-
Our findings show that the menstrual cycle affects the biodistribution of therapeutic nanoparticles towards the female reproductive system. Proper sex considerations in preclinical studies and clinical trials are encouraged, however in the field of nanotechnology these considerations are still nascent.